目的系统评价舒眠胶囊联合化学药治疗失眠症的临床疗效与安全性。方法计算机检索PubMed、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普数据库(VIP)和万方数据库,收集舒眠胶囊联合化学药(试验组)对比单用化学药(对照组)治疗失眠...目的系统评价舒眠胶囊联合化学药治疗失眠症的临床疗效与安全性。方法计算机检索PubMed、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普数据库(VIP)和万方数据库,收集舒眠胶囊联合化学药(试验组)对比单用化学药(对照组)治疗失眠症的随机对照试验(RCT),并追溯纳入研究的参考文献。检索时限为2000年1月-2017年7月。严格按照纳入与排除标准筛选文献、提取有效数据并对纳入文献进行方法学质量评价,采用Rev Man 5.0软件对各效应指标进行Meta-分析。结果共纳入10个RCT,共计1 051例失眠症患者。Meta-分析结果显示:试验组临床总有效率高于对照组[OR=2.23,95%CI(2.18,4.77),P<0.001],两组比较差异有统计学意义;试验组治疗周期末匹兹堡睡眠质量指数量表(PSQI)评分低于对照组[MD=-1.88,95%CI(-2.58,-1.17),P<0.001],差异有统计学意义;试验组与对照组不良反应发生率相当[OR=0.68,95%CI(0.33,1.40),P=0.29],差异无统计学意义。结论舒眠胶囊联合化学药治疗失眠症的临床疗效优于单用化学药治疗。由于本系统评价纳入的文献质量较低、且样本量小,尚需更多高质量RCT予以进一步的证实。展开更多
OBJECTIVE:To evaluate the clinical effectiveness of Shumian capsule(舒眠胶囊)in improving the symptoms of insomnia,anxiety,depression,and other symptoms of convalescent patients of COVID-19.METHODS:Totally 200 patient...OBJECTIVE:To evaluate the clinical effectiveness of Shumian capsule(舒眠胶囊)in improving the symptoms of insomnia,anxiety,depression,and other symptoms of convalescent patients of COVID-19.METHODS:Totally 200 patients were collected and randomly divided into experiment group(n=100)and control group(n=100).The control group was treated with Shumian capsule simulator,and the experiment group was treated with Shumian capsule.The improvement of TCM symptom score,the total effective rate and symptom disappearance rate of TCM symptoms in the two groups before and after treatment were observed,and the clinical effect was evaluated.RESULTS:One week after treatment,the scores of anxiety symptoms in the experiment group were significantly different from those in the control group(P<0.05),but there was no significant difference in the scores of insomnia and depression between the experiment group and the control group(P>0.05).There was no significant difference in the total effective rate and disappearance rate of TCM symptoms of insomnia,anxiety and depression between the experiment group and the control group(P>0.05).After 2 weeks of treatment,the scores of insomnia,anxiety,depression and the total effective rate of TCM symptoms in the experiment group were significantly different from those in the control group(P<0.05).There was no significant difference in the disappearance rate of insomnia,anxiety and depression between the experiment group and the control group(P>0.05).There were no significant differences in heart rate,respiration,systolic blood pressure and diastolic blood pressure between the experiment group and the control group(P>0.05).CONCLUSION:Shumian capsule can significantly improve the symptoms of insomnia,anxiety and depression in COVID-19’s convalescent patients with sleep and mood disorders.展开更多
文摘目的系统评价舒眠胶囊联合化学药治疗失眠症的临床疗效与安全性。方法计算机检索PubMed、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普数据库(VIP)和万方数据库,收集舒眠胶囊联合化学药(试验组)对比单用化学药(对照组)治疗失眠症的随机对照试验(RCT),并追溯纳入研究的参考文献。检索时限为2000年1月-2017年7月。严格按照纳入与排除标准筛选文献、提取有效数据并对纳入文献进行方法学质量评价,采用Rev Man 5.0软件对各效应指标进行Meta-分析。结果共纳入10个RCT,共计1 051例失眠症患者。Meta-分析结果显示:试验组临床总有效率高于对照组[OR=2.23,95%CI(2.18,4.77),P<0.001],两组比较差异有统计学意义;试验组治疗周期末匹兹堡睡眠质量指数量表(PSQI)评分低于对照组[MD=-1.88,95%CI(-2.58,-1.17),P<0.001],差异有统计学意义;试验组与对照组不良反应发生率相当[OR=0.68,95%CI(0.33,1.40),P=0.29],差异无统计学意义。结论舒眠胶囊联合化学药治疗失眠症的临床疗效优于单用化学药治疗。由于本系统评价纳入的文献质量较低、且样本量小,尚需更多高质量RCT予以进一步的证实。
基金Supported by State Administration of Traditional Chinese Medicine COVID-19 Traditional Chinese Medicine Emergency Project(the fifth batch):Study on TCM Screening for Recovery from COVID-19(No.2020ZYLCYJ08)。
文摘OBJECTIVE:To evaluate the clinical effectiveness of Shumian capsule(舒眠胶囊)in improving the symptoms of insomnia,anxiety,depression,and other symptoms of convalescent patients of COVID-19.METHODS:Totally 200 patients were collected and randomly divided into experiment group(n=100)and control group(n=100).The control group was treated with Shumian capsule simulator,and the experiment group was treated with Shumian capsule.The improvement of TCM symptom score,the total effective rate and symptom disappearance rate of TCM symptoms in the two groups before and after treatment were observed,and the clinical effect was evaluated.RESULTS:One week after treatment,the scores of anxiety symptoms in the experiment group were significantly different from those in the control group(P<0.05),but there was no significant difference in the scores of insomnia and depression between the experiment group and the control group(P>0.05).There was no significant difference in the total effective rate and disappearance rate of TCM symptoms of insomnia,anxiety and depression between the experiment group and the control group(P>0.05).After 2 weeks of treatment,the scores of insomnia,anxiety,depression and the total effective rate of TCM symptoms in the experiment group were significantly different from those in the control group(P<0.05).There was no significant difference in the disappearance rate of insomnia,anxiety and depression between the experiment group and the control group(P>0.05).There were no significant differences in heart rate,respiration,systolic blood pressure and diastolic blood pressure between the experiment group and the control group(P>0.05).CONCLUSION:Shumian capsule can significantly improve the symptoms of insomnia,anxiety and depression in COVID-19’s convalescent patients with sleep and mood disorders.
